



CEDRUS INVESTMENTS

赛 德 思 投 资

FOR IMMEDIATE RELEASE

**CEDRUS' HEAD OF LIFE SCIENCES
MS. KIMBERLY NEARING INVITED TO SPEAK AT THE
BIOCENTURY AND BAYHELIX'S CHINA HEALTHCARE SUMMIT 2018
IN SHANGHAI**

HONG KONG, 5th December 2018 – Ms. Kimberly Nearing, the **Managing Director - Life Sciences** at Cedrus Investments (“Cedrus”), was invited to speak on a panel at the 5th Annual **China Healthcare Summit in 2018 in Shanghai** hosted by **BioCentury Inc.** and **BayHelix**.

Five years ago, the first China Healthcare Summit asked how the nation would build the **“Bridge to Innovation.”** In 2018, the focus of the summit was on how China is actually building the “bridge” to global healthcare. The full two-day program on 13th and 14th November highlighted by interchange among China-facing biotech innovators and their globally-facing Chinese counterparts, plus 35 roadshow presentations and 1-on-1 meetings. During the conference, **McKinsey & Co.** delivered the key findings from its **exclusive 5th China Healthcare Summit** report to conference delegates.

The China Healthcare Summit 2018 is among the most important healthcare conferences of the year and drew over 550 participants. Conference speakers and participants represented many leading investors and corporate executives in the region and overseas. They included Nisa Leung, Managing Partner, **Qiming Partners**; Bin Li, Ph.D., CEO, **Ally Bridge LB Healthcare Fund**; Lianshan Zhang, Ph.D., SVP and President, Global R&D, **Jiangsu Hengrui Medicine Co., Ltd.**; Ruilin Song, Executive President, **PhIRDA (China Pharmaceutical Innovation and Research Development Association)**; Hyunsang Muk, President & CEO, **Korea Drug Development Fund**; Jimmy Wei, Ph.D., Managing Partner in China, **Pivotal bioVenture Partners**; James Li, M.D., CEO, **JW Therapeutics Inc.**; Thomas Willemsen, Chairman, **GlaxoSmithKline (China) Investment Co. Ltd.**; and Antoine Papiernik, Managing Partner, **Sofinnova Partners**.

Ms. Nearing participated in the summit's capstone rapporteur session, where biotech leaders from the U.S., Europe, and Asia reflected on what they had learned about China's prospects for leadership at home and abroad in innovation and entrepreneurship.

Dr. C. Simone Fishburn, VP, Executive Editor at BioCentury Inc., said the capstone panel was “great [and she] got very enthusiastic feedback...and I think it was a perfect wrap to the conference.”

--



CEDRUS INVESTMENTS
赛 德 思 投 资

About Cedrus Investments

Cedrus Investments is a global boutique investment firm headquartered in Hong Kong, specializing in Asset Management and Financial Advisory Services. Cedrus has extensive experience and a global network in the life sciences industry together with cross-border transactions track record in geographies, including China, Australia, Asia, U.S., and Europe.

SOURCE Cedrus Investments

Media Enquiry:

Cedrus Investments Ltd.

Amy Sin

+852-3519-2828

information@cedrusinvestments.com